BGPT: Author Review: Yiqing Yang

Explore by Goal

Quick Explanation Copied

What’s scientifically strongest/weakest in the provided “Yiqing Yang” research evidence

Biomarker + mechanism (sepsis-AKI axis): the dataset supports an FENDRR/miR-3614-5p regulatory link plus a reported ROC AUC (~0.91) for distinguishing AKI from sepsis (but causality and generalizability are not yet established).
Mechanistic ECM remodeling: the breast-cancer CAF/TSG-6/HA cross-linking story is experimentally multi-level (human tissue + mouse model + in vitro + “rescue”), though the human sample size (n=16) is small.
Preclinical inflammation/autophagy: the CIA study links phenotypes to autophagy markers and PI3K/AKT/mTOR inhibition via transcriptomics, but dose/trajectory, blinding, and translation remain key unknowns.

Because the prompt does not provide verifiable publication-to-author metadata (e.g., confirmed that “Yiqing Yang” is the same author on each cited DOI), this review is evidence-grade limited to what’s explicitly in the provided datasets.

Long Explanation

BGPT Author Review: “Yiqing Yang” (evidence-based, skeptical, citation-first)

Important scope constraint: the prompt provides multiple DOIs and extracted “paper data,” but it does not explicitly prove that the named person “Yiqing Yang” is the author on each DOI. Therefore, I grade the scientific strength of the provided experimental evidence, not the career-level authorship track record, and I flag where attribution cannot be verified.

1) Evidence visualized (from the provided extracted datasets)

The following plots are generated directly from the numeric summaries included in the prompt’s extracted Table/Figure fields.

Clinical separation: biomarker and severity signals (AKI vs sepsis controls)

Source: extracted clinical summary for an FENDRR biomarker/axis study in sepsis-induced AKI (Sepsis-3 + KDIGO 2012; sample n=175).

Diagnostic performance: reported ROC (AUC, sensitivity, specificity)

Source: extracted ROC summary (AUC 0.91; CI 0.868–0.952; sensitivity 0.824; specificity 0.867).

Effect direction consistency: FENDRR vs miR-3614-5p correlation (reported)

Source: extracted correlation between FENDRR and miR-3614-5p in AKI samples.

Transcriptomics quality snapshot (CIA RNA-seq excerpted read statistics)

Source: extracted RNA-seq per-sample quality metrics including Q20/Q30/error rate and GC-content.

2) Mechanistic and biomarker logic: what is supported vs what is still uncertain

2A) Sepsis-induced AKI: FENDRR → miR-3614-5p (reported) → inflammation/oxidative stress phenotypes

Supported by correlation + functional perturbation (in vitro): the extracted dataset reports that in AKI patients, FENDRR correlates with clinical severity indicators and that silencing FENDRR in HK-2 cells reduces LPS-induced oxidative/inflammatory readouts and reverses apoptosis/viability changes.
Supported by direct binding claim: a dual-luciferase reporter experiment is reported as testing WT/MUT binding between FENDRR and miR-3614-5p.
Diagnostic utility is quantitatively reported: ROC AUC ~0.91 is reported, with accompanying sensitivity/specificity.

Key scientific uncertainties / potential blind spots

Observational confounding risk: the extracted dataset itself flags that the clinical component is single-center/observational and may have confounding; logistic models are reported, but the prompt notes not all confounders may be fully adjusted.
Model transfer risk (HK-2 + LPS): HK-2 LPS exposure is a simplified proxy for sepsis-AKI; without additional models, the mechanistic axis may not fully reflect in vivo kidney injury diversity.

2B) Breast cancer CAF microenvironment: TSG-6 restores HA cross-linking and suppresses malignancy

Multi-modal evidence chain: the extracted summary reports human tissue staining (HA–Iα-I complexes and TSG-6), fibroblast source comparisons (NFbs vs CAFs), molecular modulation using lentiviral TSG-6 constructs, and both in vitro and orthotopic in vivo tumor assays.
“Rescue” logic is present: the extracted summary reports that restoring TSG-6 (including WT vs catalytically inactive controls) increases HA cross-linking and suppresses tumor aggressiveness measures.

Key scientific uncertainties / potential blind spots

Small human cohort: the extracted summary indicates human samples n=16, with very limited staging resolution (Stage I n=7, Stage III n=9).
Proxy measurement risk: the extracted limitations note cross-linking assessment relies on proxies/surrogate markers and not direct quantification in all contexts.
Model generalizability: the extracted summary highlights that the MMTV-PyMT model may not recapitulate full human heterogeneity.

2C) CIA (mouse) inflammation: melittin acupoint injection → autophagy activation + PI3K/AKT/mTOR inhibition (reported)

Phenotype-to-mechanism linkage is attempted: the extracted dataset reports arthritis index reductions, cytokine shifts (TNF-α, IL-1β, IL-17A, IL-10), autophagy marker changes (LC3B, ULK1/Beclin-1/p62), and PI3K/Akt/mTOR signaling readouts.
Transcriptomics enrichment is reported: the extracted dataset reports RNA-seq differential expression counts and pathway enrichments including autophagy and PI3K/AKT/mTOR-related pathways.

Key scientific uncertainties / potential blind spots

Translation limits: the extracted limitations emphasize that mouse CIA may not translate cleanly to human RA.
Blinding/adverse events and autophagy depth: the extracted prompt lists potential incomplete mechanistic exploration and mentions possible injection-related issues.

3) Overall scientific strength judgment (graded to the provided evidence only)

Strength: the provided evidence includes mechanistic perturbations (si/overexpression; lentiviral modulation), multiple readouts (cell phenotypes + molecular markers), and at least one study with a relatively stronger “rescue” logic (CAF-dependent HA cross-linking).
Weakness: two major credibility anchors remain under-specified in the prompt: (i) external validity/generalizability (single-center, small cohorts, simplified models), and (ii) causal completeness (downstream pathway mapping beyond the core axis is not fully established in the extracted summaries).

Confidence: moderate about the directional quality of the evidence (because the extracted datasets explicitly describe perturbations and assays), but low about who “Yiqing Yang” is across the DOIs because attribution isn’t explicitly established in the prompt.

Feedback:

Updated: April 10, 2026